BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai B, Dongiovanni P, Corey KE, Wang X, Shmarakov IO, Zheng Z, Kasikara C, Davra V, Meroni M, Chung RT, Rothlin CV, Schwabe RF, Blaner WS, Birge RB, Valenti L, Tabas I. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2020;31:406-421.e7. [PMID: 31839486 DOI: 10.1016/j.cmet.2019.11.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Yu S, Hu X, Li Y, You X, Tian D, Cheng L, Zheng M, Jing J. Fibrotic Scar After Spinal Cord Injury: Crosstalk With Other Cells, Cellular Origin, Function, and Mechanism. Front Cell Neurosci 2021;15:720938. [PMID: 34539350 DOI: 10.3389/fncel.2021.720938] [Reference Citation Analysis]
2 Zhang C, Yang M, Ericsson AC. Function of Macrophages in Disease: Current Understanding on Molecular Mechanisms. Front Immunol 2021;12:620510. [PMID: 33763066 DOI: 10.3389/fimmu.2021.620510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Xu R, Zhao L, Liu J, Cao L, Zhao T, Yu Y, Xuan D, Wan W, Xue Y, Zou H, M.a B. Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages. Journal of Healthcare Engineering 2022;2022:1-14. [DOI: 10.1155/2022/9241835] [Reference Citation Analysis]
4 Wang Z, Yang X, Gui S, Yang F, Cao Z, Cheng R, Xia X, Li C. The Roles and Mechanisms of lncRNAs in Liver Fibrosis. Front Pharmacol 2021;12:779606. [PMID: 34899344 DOI: 10.3389/fphar.2021.779606] [Reference Citation Analysis]
5 Lu S, Wang Y, Liu J. TNF-α signaling in non-alcoholic steatohepatitis and targeted therapies. J Genet Genomics 2021:S1673-8527(21)00337-4. [PMID: 34757037 DOI: 10.1016/j.jgg.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang Y, Wang H, Li G, Liu Y, Wang C, He D. Exploring the genetic basis of fatty liver development in geese. Sci Rep 2020;10:14279. [PMID: 32868783 DOI: 10.1038/s41598-020-71210-8] [Reference Citation Analysis]
7 Hu J, Ying H, Yao J, Yang L, Jin W, Ma H, Li L, Zhao Y. Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy. Front Pharmacol 2021;12:744483. [PMID: 34712137 DOI: 10.3389/fphar.2021.744483] [Reference Citation Analysis]
8 Wang S, Shi K, Lu J, Sun W, Han Q, Che L, Zhang D. Microsphere-Embedded Hydrogel Sustained-Release System to Inhibit Postoperative Epidural Fibrosis. ACS Appl Bio Mater 2021;4:5122-31. [PMID: 35007060 DOI: 10.1021/acsabm.1c00347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
10 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Flint E, Triantafyllou E, Bernsmeier C. TAM Receptors in the Pathophysiology of Liver Disease. Livers 2022;2:15-29. [DOI: 10.3390/livers2010002] [Reference Citation Analysis]
12 Gerlach BD, Ampomah PB, Yurdagul A Jr, Liu C, Lauring MC, Wang X, Kasikara C, Kong N, Shi J, Tao W, Tabas I. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab 2021:S1550-4131(21)00527-1. [PMID: 34784501 DOI: 10.1016/j.cmet.2021.10.015] [Reference Citation Analysis]
13 Walsh AD, Johnson LJ, Harvey AJ, Kilpatrick TJ, Binder MD, Burstyn-cohen T, Quan N. Identification and Characterisation of cis-Regulatory Elements Upstream of the Human Receptor Tyrosine Kinase Gene MERTK. BPL 2021;7:3-16. [DOI: 10.3233/bpl-200102] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gadiyar V, Patel G, Davra V. Immunological role of TAM receptors in the cancer microenvironment. Int Rev Cell Mol Biol 2020;357:57-79. [PMID: 33234245 DOI: 10.1016/bs.ircmb.2020.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Reference Citation Analysis]
16 Lis-López L, Bauset C, Seco-Cervera M, Cosín-Roger J. Is the Macrophage Phenotype Determinant for Fibrosis Development? Biomedicines 2021;9:1747. [PMID: 34944564 DOI: 10.3390/biomedicines9121747] [Reference Citation Analysis]
17 Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs 2021;30:429-38. [PMID: 33322977 DOI: 10.1080/13543784.2021.1865308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Junior, Lai YS, Nguyen HT, Salmanida FP, Chang KT. MERTK+/hi M2c Macrophages Induced by Baicalin Alleviate Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:10604. [PMID: 34638941 DOI: 10.3390/ijms221910604] [Reference Citation Analysis]
19 Engelmann C, Tacke F. The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:652. [PMID: 35054837 DOI: 10.3390/ijms23020652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
20 Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Front Immunol 2020;11:1169. [PMID: 32670278 DOI: 10.3389/fimmu.2020.01169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Cai B, Kasikara C. TAM receptors and their ligand-mediated activation: Role in atherosclerosis. Int Rev Cell Mol Biol 2020;357:21-33. [PMID: 33234243 DOI: 10.1016/bs.ircmb.2020.09.001] [Reference Citation Analysis]
22 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Im YR, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD. Hepatology 2021;74:1884-901. [PMID: 33973269 DOI: 10.1002/hep.31897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
24 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Kragh Petersen S, Bilkei-Gorzo O, Govaere O, Härtlova A. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol 2020;92:e12971. [PMID: 32892401 DOI: 10.1111/sji.12971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S, Loomba R. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;51:1305-20. [PMID: 32383295 DOI: 10.1111/apt.15738] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
27 Wang Q, Zhou H, Bu Q, Wei S, Li L, Zhou J, Zhou S, Su W, Liu M, Liu Z, Wang M, Lu L. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Meroni M, Longo M, Tria G, Dongiovanni P. Genetics Is of the Essence to Face NAFLD. Biomedicines 2021;9:1359. [PMID: 34680476 DOI: 10.3390/biomedicines9101359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
30 Wen Y, Ju C. MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis. Hepatology 2020;72:772-4. [PMID: 32171039 DOI: 10.1002/hep.31233] [Reference Citation Analysis]
31 Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 2021;18:45-56. [PMID: 33041338 DOI: 10.1038/s41423-020-00558-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
32 Wang S, Gao S, Li Y, Qian X, Luan J, Lv X. Emerging Importance of Chemokine Receptor CXCR4 and Its Ligand in Liver Disease. Front Cell Dev Biol 2021;9:716842. [PMID: 34386499 DOI: 10.3389/fcell.2021.716842] [Reference Citation Analysis]
33 Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacol Ther 2020;213:107577. [PMID: 32417270 DOI: 10.1016/j.pharmthera.2020.107577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
34 [DOI: 10.1101/2020.12.26.20248491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Chen X, Wang Z, Han S, Wang Z, Zhang Y, Li X, Xia N, Yu W, Jia C, Ni Y, Pu L. Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment. Cell Death Dis 2021;12:1123. [PMID: 34853322 DOI: 10.1038/s41419-021-04403-2] [Reference Citation Analysis]
36 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
37 He W, Huang C, Zhang X, Wang D, Chen Y, Zhao Y, Li X. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine 2021;73:52-64. [PMID: 33837926 DOI: 10.1007/s12020-021-02716-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Rovati L, Kaneko N, Pedica F, Monno A, Maehara T, Perugino C, Lanzillotta M, Pecetta S, Stone JH, Doglioni C, Manfredi AA, Pillai S, Della-Torre E. Mer tyrosine kinase (MerTK) as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease. Rheumatology (Oxford) 2021:keab096. [PMID: 33512463 DOI: 10.1093/rheumatology/keab096] [Reference Citation Analysis]
39 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
40 Almishri W, Swain LA, D'Mello C, Le TS, Urbanski SJ, Nguyen HH. ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice. Front Immunol 2021;12:779119. [PMID: 35095853 DOI: 10.3389/fimmu.2021.779119] [Reference Citation Analysis]
41 Zhang H, Ma Y, Cheng X, Wu D, Huang X, Chen B, Ren Y, Jiang W, Tang X, Bai T, Chen Y, Zhao Y, Zhang C, Xiao X, Liu J, Deng Y, Ye T, Chen L, Liu HM, Friedman SL, Chen L, Ding BS, Cao Z. Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2021;13:eabd1206. [PMID: 34613814 DOI: 10.1126/scitranslmed.abd1206] [Reference Citation Analysis]
42 Clarke J, Yaqubi M, Futhey NC, Sedaghat S, Baufeld C, Blain M, Baranzini S, Butovsky O, Antel J, White JH, Healy LM. Vitamin D Regulates MerTK-Dependent Phagocytosis in Human Myeloid Cells. J Immunol 2020;205:398-406. [PMID: 32540991 DOI: 10.4049/jimmunol.2000129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). IJMS 2022;23:6996. [DOI: 10.3390/ijms23136996] [Reference Citation Analysis]
44 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
45 AbdelMassih AF, Kamel A, Mishriky F, Ismail HA, El Qadi L, Malak L, El-Husseiny M, Ashraf M, Hafez N, AlShehry N, El-Husseiny N, AbdelRaouf N, Shebl N, Hafez N, Youssef N, Afdal P, Hozaien R, Menshawey R, Saeed R, Fouda R. Is it infection or rather vascular inflammation? Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in COVID-19. Cardiovasc Endocrinol Metab 2020;9:110-20. [PMID: 32803145 DOI: 10.1097/XCE.0000000000000211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
46 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zagórska A, Través PG, Jiménez-García L, Strickland JD, Oh J, Tapia FJ, Mayoral R, Burrola P, Copple BL, Lemke G. Differential regulation of hepatic physiology and injury by the TAM receptors Axl and Mer. Life Sci Alliance 2020;3:e202000694. [PMID: 32571802 DOI: 10.26508/lsa.202000694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
48 He X, Hong W, Yang J, Lei H, Lu T, He C, Bi Z, Pan X, Liu Y, Dai L, Wang W, Huang C, Deng H, Wei X. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduct Target Ther 2021;6:270. [PMID: 34262012 DOI: 10.1038/s41392-021-00688-z] [Reference Citation Analysis]
49 Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne) 2020;11:601290. [PMID: 33381084 DOI: 10.3389/fendo.2020.601290] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Reference Citation Analysis]
51 Bhave S, Ho HK. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1776. [PMID: 34944593 DOI: 10.3390/biomedicines9121776] [Reference Citation Analysis]
52 Mederacke I, Filliol A, Affo S, Nair A, Hernandez C, Sun Q, Hamberger F, Brundu F, Chen Y, Ravichandra A, Huebener P, Anke H, Shi H, Martínez García de la Torre RA, Smith JR, Henderson NC, Vondran FWR, Rothlin CV, Baehre H, Tabas I, Sancho-Bru P, Schwabe RF. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. Sci Transl Med 2022;14:eabe5795. [PMID: 35385339 DOI: 10.1126/scitranslmed.abe5795] [Reference Citation Analysis]
53 Yang S, Wang X, Xiao W, Xu Z, Ye H, Sha X, Yang H. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves’ Ophthalmopathy by Targeting Orbital Fibroblasts. Front Endocrinol 2022;13:891922. [DOI: 10.3389/fendo.2022.891922] [Reference Citation Analysis]
54 Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020;72:1196-209. [PMID: 32145256 DOI: 10.1016/j.jhep.2020.02.020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 32.5] [Reference Citation Analysis]
55 Wanke F, Gutbier S, Rümmelin A, Steinberg M, Hughes LD, Koenen M, Komuczki J, Regan-Komito D, Wagage S, Hesselmann J, Thoma R, Brugger D, Christopeit T, Wang H, Point F, Hallet R, Ghosh S, Rothlin CV, Patsch C, Geering B. Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages. Cell Death Dis 2021;12:538. [PMID: 34035216 DOI: 10.1038/s41419-021-03770-0] [Reference Citation Analysis]
56 Wang X, Cai B. MerTK, a risk factor for NASH fibrosis. Aging (Albany NY) 2020;12:19832-3. [PMID: 33125345 DOI: 10.18632/aging.104210] [Reference Citation Analysis]
57 Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Pastore M, Caligiuri A, Raggi C, Navari N, Piombanti B, Di Maira G, Rovida E, Piccinni M, Lombardelli L, Logiodice F, Rombouts K, Petta S, Marra F. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100444] [Reference Citation Analysis]
60 Cheng D, Chai J, Wang H, Fu L, Peng S, Ni X. Hepatic macrophages: Key players in the development and progression of liver fibrosis. Liver Int 2021. [PMID: 33966318 DOI: 10.1111/liv.14940] [Reference Citation Analysis]
61 Al-Salihi M, Bornikoel A, Zhuang Y, Stachura P, Scheller J, Lang KS, Lang PA. The role of ADAM17 during liver damage. Biol Chem 2021;402:1115-28. [PMID: 34192832 DOI: 10.1515/hsz-2021-0149] [Reference Citation Analysis]
62 Trivedi P, Wang S, Friedman SL. The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells. Cell Metab 2021;33:242-57. [PMID: 33232666 DOI: 10.1016/j.cmet.2020.10.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]